Since we found that SMAD2 phosphorylation is significantly higher in cachectic muscles from the Bard1‐deficient, orthotopic model compared to control muscles, it is plausible that the TGF‐β pathway regulates Zip14 expression during breast cancer metastasis and that the new class of TGF‐β pathway inhibitors that is currently being tested in clinical trials44 could be useful for the treatment of breast cancer‐associated cachexia. This evidence concerns the gene BARD1 and breast carcinoma.